Breaking News Instant updates and real-time market news.

ESPR

Esperion

$12.32

-0.58 (-4.50%)

07:40
10/13/16
10/13
07:40
10/13/16
07:40

Esperion says bempedoic acid Phase 3 program to include any statin at any dose

Esperion announced the bempedoic acid global pivotal Phase 3 LDL-C lowering clinical development program will include patients with hypercholesterolemia on any statin at any dose based on positive top-line results from its Phase 2 pharmacokinetics and pharmacodynamics study of bempedoic acid added to atorvastatin 80 mg, and the previously completed Phase 1 and Phase 2 studies.

  • 06

    Nov

ESPR Esperion
$12.32

-0.58 (-4.50%)

06/29/16
06/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. HeartWare (HTWR) downgraded to Equal Weight from Overweight at Barclays by analyst Matthew Taylor, saying he does not expect a competing takeover bid to Medtronic's (MDT) offer. The analyst raised his price target for the shares to $58 from $35. Similarly, shares were downgraded to Market Perform from Outperform at Wells Fargo, with analyst Larry Biegelsen saying he sees a low likelihood that a higher bidder will emerge. The analyst believes Medtronic paid a fair valuation for HeartWare. HeartWare was also downgraded to Neutral from Buy at BTIG. 2. Esperion (ESPR) downgraded to Neutral from Overweight at JPMorgan by analyst Jessica Fye, who slashed her price target for shares to $15 from $50. The analyst says last night's regulatory update is a net negative. Disappointingly, the FDA did not sign off on the use of LDL-C lowering as an acceptable regulatory endpoint for approval of bempedoic acid for the treatment of statin-intolerant patients, Fye tells investors in a research note. The analyst still believes bempedoic acid is an effective LDL-C lowering agent, but now sees a drawn out path to approval in the U.S. Esperion was also downgraded to Underperform at Neutral at Credit Suisse by analyst Vamil Divan, who says the update on the development plans for bempedoic acid leaves him increasingly concerned about the products outlook in the U.S. market. The analyst was surprised that the FDA may not be willing to allow LDL-C as a surrogate endpoint for initial approval but believes there will be significant pressure, and limited upside, on shares until that certainty is obtained, and that process may take years to play out. Esperion was also downgraded to Sector Perform from Outperform at RBC Capital. 3. Comerica (CMA) downgraded to Underperform from Neutral at BofA/Merrill, which reduced its price target to $36 from $45. The firm's analyst lowered estimates 8% below consensus for 2016 and 17% below consensus in 2017 due to low rates that will pressure spread revenue growth, slower U.S. economic growth, and continued reserve build. The firm also downgraded Regions Financial (RF), Synovus (SNV), Texas Capital (TCBI) and Franklin Financial Network (FSB) to Neutral from Buy, as well as Zions Bancorp (ZION) to Underperform from Neutral. 4. comScore (SCOR) downgraded to Neutral from Positive at Susquehanna, citing uncertainty surrounding its accounting issues. The firm continues to like the long-term fundamental story, but with an unclear timeline for its resolution, they are moving to the sidelines. Susquehanna lowered its price target to $18 from $30 on comScore shares. 5. Harman (HAR) downgraded to Sector Perform from Outperform at RBC Capital partly based on the low number of new car launches next year, the firm's forecast for reduced production by the company's European customers, and the firm's reduction in its U.S. auto production versus its previous forecast. Additionally, the firm expects GM (GM) to delay a number of its connected car launches that had been slated for fiscal 2017 until fiscal 2018. The firm lowered its price target to $73 from $85. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/16
LEHM
06/29/16
DOWNGRADE
LEHM
Equal Weight
Esperion downgraded to Equal Weight from Overweight at Barclays
07/05/16
UBSW
07/05/16
DOWNGRADE
Target $11
UBSW
Neutral
Esperion downgraded to Neutral from Buy at UBS
UBS analyst Jeffrey Hung downgraded Esperion Therapeutics to Neutral citing an uncertain U.S. regulatory pathway after the FDA did not specifically state that LDL-lowering data could be used for accelerated approval. The analyst cut his price target for the shares to $11 from $69.
07/05/16
WBTH
07/05/16
DOWNGRADE
WBTH
Hold
Esperion downgraded to Hold from Buy at WallachBeth (pre-open)

TODAY'S FREE FLY STORIES

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

, AVXS

AveXis

$76.76

-0.24 (-0.31%)

07:23
04/24/17
04/24
07:23
04/24/17
07:23
Conference/Events
American Academy of Neurology »

69th Annual Meeting of…

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

AVXS

AveXis

$76.76

-0.24 (-0.31%)

CATB

Catabasis Pharmaceuticals

$1.45

-0.07 (-4.61%)

MNOV

MediciNova

$5.83

0.08 (1.39%)

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

FLKS

Flex Pharma

$3.08

-0.5 (-13.97%)

TGTX

TG Therapeutics

$10.30

-0.15 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 24

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 24

    Aug

VAC

Marriott Vacations

$104.42

1.54 (1.50%)

, WYN

Wyndham

$89.72

-0.03 (-0.03%)

07:22
04/24/17
04/24
07:22
04/24/17
07:22
Recommendations
Marriott Vacations, Wyndham, Extended Stay America analyst commentary  »

A few hotel chanins…

VAC

Marriott Vacations

$104.42

1.54 (1.50%)

WYN

Wyndham

$89.72

-0.03 (-0.03%)

STAY

Extended Stay America

$17.24

-0.07 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 04

    May

CGIX

Cancer Genetics

$4.05

0.1 (2.53%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Hot Stocks
Cancer Genetics launches Complete::IO panel »

Cancer Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$119.10

0.22 (0.19%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Upgrade
Travelers rating change  »

Travelers upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLT

FleetCor

$147.66

-2.07 (-1.38%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Recommendations
FleetCor analyst commentary  »

FleetCor should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

DB

Deutsche Bank

$16.50

-0.05 (-0.30%)

07:21
04/24/17
04/24
07:21
04/24/17
07:21
Technical Analysis
Deutsche Bank rallies sharply in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

, FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

07:20
04/24/17
04/24
07:20
04/24/17
07:20
Conference/Events
RLJ Lodging Trust and Felcor Lodging to host joint conference call »

Joint Conference call to…

RLJ

RLJ Lodging Trust

$23.60

-0.2 (-0.84%)

FCH

Felcor Lodging

$7.32

-0.05 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 28

    Apr

AKTX

Akari Therapeutics

$20.50

4.13 (25.23%)

07:16
04/24/17
04/24
07:16
04/24/17
07:16
Hot Stocks
Akari: Interim Phase 2 PNH data demonstrate 'positive' response with Coversin »

Akari Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

WGO

Winnebago

$26.25

0.15 (0.57%)

07:15
04/24/17
04/24
07:15
04/24/17
07:15
Initiation
Winnebago initiated  »

Winnebago initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$104.89

0.01 (0.01%)

07:14
04/24/17
04/24
07:14
04/24/17
07:14
Periodicals
Chevron to sell Bangladesh gas fields to Himalaya Energy, Reuters says »

Chevron has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

QTS

QTS Realty Trust

$52.90

-0.14 (-0.26%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

07:12
04/24/17
04/24
07:12
04/24/17
07:12
Hot Stocks
Cara Therapeutics announces 'positive' data from Phase 1 trial of CR845 »

Cara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Steel Dynamics rating change  »

Steel Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.72

-0.1 (-1.47%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
AK Steel rating change  »

AK Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

NUE

Nucor

$60.00

-0.35 (-0.58%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
Nucor rating change  »

Nucor upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.42

-0.09 (-0.29%)

07:10
04/24/17
04/24
07:10
04/24/17
07:10
Upgrade
U.S. Steel rating change  »

U.S. Steel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
Breaking Hot Stocks news story on AkzoNobel, PPG »

AkzoNobel confirms third…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

SAGE Therapeutics

$72.82

1.19 (1.66%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
SAGE Therapeutics appoints Michael Cloonan as Chief Business Officer »

Sage Therapeutics (SAGE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOMA

XOMA

$7.73

0.26 (3.48%)

07:09
04/24/17
04/24
07:09
04/24/17
07:09
Hot Stocks
XOMA says X213 shown to be safe and effective in phase 2 study »

XOMA Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

AMDA

Amedica

$0.38

0.01 (2.70%)

07:08
04/24/17
04/24
07:08
04/24/17
07:08
Hot Stocks
Amedica announces regulatory clearance to market, sell Valeo in Australia »

Amedica Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.94

-0.09 (-0.22%)

, JPM

JPMorgan

$84.52

-1.03 (-1.20%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Periodicals
HSBC selected to advise on $100B Aramco IPO, Reuters reports »

HSBC (HSBC) has been…

HSBC

HSBC

$39.94

-0.09 (-0.22%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 19

    May

  • 22

    May

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

AKER

Akers Biosciences

$1.80

0.1 (5.88%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
Akers Biosciences says digital apps approved by Apple Store »

Akers Biosciences …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHT

DHT Holdings

$4.60

-0.05 (-1.08%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Hot Stocks
DHT Holdings announces delivery of two VLCCs from BW Group »

DHT Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFR

Colony Starwood Homes

$34.82

0.12 (0.35%)

07:07
04/24/17
04/24
07:07
04/24/17
07:07
Initiation
Colony Starwood Homes initiated  »

Colony Starwood Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

, PPG

PPG

$105.94

-0.43 (-0.40%)

07:06
04/24/17
04/24
07:06
04/24/17
07:06
Hot Stocks
AkzoNobel says will 'carefully review' PPG's third unsolicited proposal »

Akzo Nobel N.V. (AKZOY)…

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

PPG

PPG

$105.94

-0.43 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.